

## Strong Proof-of-Concept for broadly protective flu cVLP vaccine further strengthens confidence in Coronavirus vaccine

**Hørsholm, Denmark, July 17, 2020 – AdaptVac, today announced publication of a paper in the journal Vaccines, where its broadly protective Flu cVLP vaccine induced a more potent, long-lasting immune response and was able to protect mice against both homologous and heterologous H1N1 influenza challenge, even after a single dose.**

“These very promising results demonstrate the potential of the cVLP platform to be protective even after a single vaccine dose. In light of AdaptVac’s focus on COVID-19, this is an extremely encouraging verification of the efficacy of the platform for respiratory viruses.” said Wian de Jongh, AdaptVac’s CEO.

Paper reference: Vaccines 2020, 8, 389; doi:10.3390/vaccines8030389  
<https://www.mdpi.com/2076-393X/8/3/389#abstract>

For further information about AdaptVac ApS, please contact:  
Dr. Wian de Jongh, CEO  
Telephone: +45 26394649  
E-mail: [wdj@adaptvac.com](mailto:wj@adaptvac.com)

### **About AdaptVac**

AdaptVac is a joint venture between ExpresS2ion Biotechnologies and NextGen Vaccines, owned by the inventors of the novel proprietary and ground-breaking viral capsid-like virus particle (CLP) platform technology spun out from the University of Copenhagen. The Company aims to accelerate the development of highly efficient therapeutic and prophylactic vaccines within high value segments of oncology, infectious diseases and immunological disorders. Granting of the core patent in the U.S. has expanded AdaptVac’s patent protection to include our entire pipeline of vaccines and immunotherapies in development. Please visit: [www.AdaptVac.com](http://www.AdaptVac.com)

*This press release was submitted for publication through the agency of the contact person set out above on July 17, 2020.*